Cargando…
Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate
The emergence of additional chromosome abnormalities (ACAs) in chronic myeloid leukemia (CML) patients during treatment with a tyrosine kinase inhibitor (TKI) regime is generally associated with resistance to treatment and a sign of disease progression to accelerated phase or blast phase. We report...
Autores principales: | Siti Mariam, Ismail, Norhidayah, Ramli, Zulaikha, Abu Bakar, Nazihah, Mohd Yunus, Rosline, Hassan, Kausar, Ghazali Anis, Sarina, Sulong, Azlan, Husin, Ankathil, Ravindran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393706/ https://www.ncbi.nlm.nih.gov/pubmed/36003793 http://dx.doi.org/10.3389/fonc.2022.720845 |
Ejemplares similares
-
Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients
por: Annuar, Aziati Azwari, et al.
Publicado: (2021) -
HOXA4 Gene Promoter Hypermethylation as an Epigenetic Mechanism Mediating Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients
por: Elias, Marjanu Hikmah, et al.
Publicado: (2013) -
Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
por: Elias, Marjanu Hikmah, et al.
Publicado: (2012) -
Hyperdiploid Multiple Myeloma with Novel Complex Structural Chromosome Abnormalities Associated with Poor Prognosis : A Rare Case Report
por: Ankathil, Ravindran, et al.
Publicado: (2021) -
Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia
por: Maddin, Najlaa, et al.
Publicado: (2016)